End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.03 USD | +1.17% | -15.78% | -28.64% |
Jun. 03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
May. 30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.